| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c10ac713fadc8d725c86a7fd91214fb7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2510-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2006-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0388cfceed51aecfdda0eed740bf3731
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9261d74942413bb2c2fc1fa8e413e39f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebec1ceb338701d012d8103d4e4f4c23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11d46d4a1dbb5da1ae76a21f7b1016df |
| publicationDate |
2007-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2617642-A1 |
| titleOfInvention |
Treatment of proliferative disorders |
| abstract |
The application discloses a method of identifying compound for the treatment of proliferative disorders that comprises testing compounds for its binding affinity to clAP-1. Preferentially compounds are selected which have a higher affinity for clAP-1 than for XIAP. In a related method, compounds causing faster degradation of clAP-1 than of XIAP are identified. Identified compounds can be peptidomimetics of the N-terminal four amino acids of SMAC. Furthermore, the application discloses methods and compositions for the treatment of proliferative diseases using compounds with the above described clAP-1 binding properties. |
| priorityDate |
2005-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |